TNGX 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分優異，但股利評分未超過2分，若公司開始配息，可能會有更優異的投資結果
TNGX 近期報酬表現
-0.13%
Tango therapeutics inc
2.35%
同產業平均
-0.21%
S&P500
與 TNGX 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
VTGN | Vistagen therapeutics, inc. | 4 分 | 3 分 | 2 分 | 2 分 | 1 分 | |
RENB | Renovaro inc | 2 分 | 1 分 | 1 分 | - | 1 分 | |
NKTR | Nektar therapeutics | 4 分 | 5 分 | 3 分 | 2 分 | 1 分 | |
PSTX | Poseida therapeutics inc | 3 分 | 3 分 | 2 分 | 3 分 | 1 分 | |
NMRA | Neumora therapeutics inc | - | 2 分 | 1 分 | 2 分 | 1 分 |
- VTGN Vistagen therapeutics, inc.價值 4 分趨勢 3 分波段 2 分籌碼 2 分股利 1 分查看更多
TNGX 公司資訊
Tango Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering precision medicine for the treatment of cancer. The Company leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing. Its lead program, TNG908, is an methylthioadenosine (MTA)-cooperative inhibitor of protein arginine methyltransferase 5 (PRMT5) designed to work selectively in cancer cells with an methylthioadenosine phosphorylase (MTAP) deletion. Its TNG260 is a first-in-class Co-repressor of Repressor Element-1 Silencing Transcription (CoREST) inhibitor. The Company's programs also include TNG348 and TNG462. TNG348 is an allosteric inhibitor of ubiquitin-specific protease (USP1).